Morten Olesen
About Morten Olesen
Morten Olesen is the Business Unit Director of Innovative Medicine at Bristol-Myers Squibb, with over 25 years of experience in the pharmaceutical and healthcare industry.
Current Role at Bristol-Myers Squibb
Morten Olesen currently holds the position of Business Unit Director, Innovative Medicine at Bristol-Myers Squibb. He started this role in April 2020 and is responsible for overseeing innovative medical projects within the company. His role involves strategic oversight and management of various initiatives aimed at advancing Bristol-Myers Squibb's footprint in the innovative medicine sector.
Previous Experience at Actelion
Before joining Bristol-Myers Squibb, Morten Olesen worked at Actelion as Business Director for Norway and Denmark from 2017 to 2019. During his two-year tenure, he was in charge of overseeing operations in the pharmaceutical industry for these two regions. His responsibilities included strategic planning and management, which played a crucial role in the company's regional success.
Career at Ferring Pharmaceuticals
Morten Olesen served as a Product Specialist at Ferring Pharmaceuticals from 1996 to 1998. Over the course of two years, he specialized in various pharmaceutical products, contributing to the company's product management and development processes. His role as a product specialist involved detailed knowledge and expertise in the pharmaceutical sector.
Early Career at GEA Group
Morten Olesen began his professional journey as a Laborant at GEA Group, where he worked from 1992 to 1996. Over four years, he gained valuable experience in laboratory operations and procedures. This foundational role helped him build a strong base in the pharmaceutical and healthcare industry, leading to further career advancements.
Educational Background
Morten Olesen's educational background is extensive. He completed an executive education program at the AVT Institute from 2008 to 2009. Prior to that, he studied at the Copenhagen Business School from 2002 to 2006, gaining a comprehensive understanding of business principles. He also pursued additional education during 2006-2007, further enhancing his expertise in the field. His educational journey has equipped him with the skills needed for his various roles in the pharmaceutical industry.